Amarin reported $36.57M in Selling and Administration Expenses for its fiscal quarter ending in March of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Alnylam Pharmaceuticals USD 323.31M 83.36M Jun/2025
Amarin USD 36.57M 397K Mar/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
DBV Technologies USD 6.81M 2.5M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
Halozyme Therapeutics USD 33M 9.36M Jun/2025
Ionis Pharmaceuticals USD 90.6M 14.6M Jun/2025
Neurocrine Biosciences USD 286.3M 9.8M Jun/2025
Novartis USD 3.44B 384M Jun/2025